Anavex Life Sciences Corp (AVXL)

[raja48185]

Anavex “has surpassed by 50% the company’s original enrollment target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 study in Rett syndrome.” So, Anavex has more patients in the study in the United States than it originally planned to enroll here in the U.S.?

I am assuming that the caretakers have been spreading the word around (and are happy to do that) in the Rett community about A2-73.